



2007 CANCER CENTER ANNUAL REPORT



REFLECTING 2006 DATA & ACTIVITIES



COMPREHENSIVE CANCER COMMITTEE CHARIMAN'S REPORT FOR 2007

by Jimmie Harvey, M.D.


The Comprehensive Cancer Committee at Trinity Medical Center is pleased to present the 2007 Annual Report reflecting data from the 2006 calendar year. Our program provides a comprehensive network of oncology services specializing in the prevention, diagnosis, treatment and management of patients with cancer. Through the dedicated efforts of individuals on the Comprehensive Cancer Committee we are able to coordinate a multidisciplinary approach, maximizing teamwork among clinical and ancillary services. Our goal is to decrease the morbidity and mortality caused by cancer through prevention, monitoring and reporting of care, standard setting and education as well as supporting the physical, emotional and spiritual components of care for our patients. We continue refining our program components insuring quality of care and compliance to the standards of the American College of Surgeons Commission on Cancer.

A total of 774 new cases were added to the Cancer Data Registry for 2006 with 102 of them being non-analytic cases. Non-analytic cases are those diagnosed and the first course of treatment provided elsewhere. The new number of cases brings the total in the database to 19,730 since the reference date of 1984. A total of 109 cases were presented at 40 tumor board meetings. Of the cases presented 92 were prospective and 17 were retrospective.

Our Clinical, Quality Improvement, Programmatic and Community Outreach Goals were met for the year. We are very proud of the hard work that went into meeting these goals.

Montclair Baptist Medical Center officially became Trinity Medical Center on May 3, 2006. The name change announcement was made on the plaza in front of the hospital with a banner drop and releasing of doves. The sculpture "Triumph" by Branko Medenica was unveiled on the front plaza as well that day. The Women's Boutique opened in July, 2006. This unique boutique offers wigs, prosthesis, lingerie, etc. Our cancer patients have many beneficial items offered to them through the boutique.

Finally, I am pleased to report that the Commission on Cancer survey team awarded us with the highest approval rating, "Three-year approval with Commendations" as a Teaching Hospital Comprehensive Cancer Program. This designation is only awarded to comprehensive programs that meet high standards of practice in all components of service essential to providing high quality cancer care.





COMPREHENSIVE CANCER COMMITTEE

The Cancer Committee at Trinity Medical Center is a standing committee of the hospital's medical staff to provide high quality, multidisciplinary cancer care. The Committee is dedicated to providing cancer prevention, education and support programs for patient needs and to ensure that patients diagnosed with a malignancy have access to the most effective treatment available. The Cancer Committee meets quarterly and includes multidisciplinary physician members from the diagnostic and therapeutic specialties, as well as allied health professionals involved in the care of cancer patients. The program's goals and success depends on the Committee's leadership to plan, implement and evaluate cancer patient care and other cancer-related activities at Trinity.

COMMITTEE MEMBERS:

Chairman: Jimmie Harvey, MD, Medical Oncology

Coordinators

Cancer Conference: Annette Entrekin, RHIT, CTR, Cancer Data Coder

Cancer Registry: Connie Jensen, RHIT, CTR, Cancer Data Coder
Jane Northcutt, RN, BSN, Manager

Quality Improvement: Jennifer Perrigin, RN, Quality Management PI Coordinator

Community Outreach: Leisha Harris, Marketing Director/ E. Shields Frey, MD

Other Members

J. Maxwell Austin, MD, OB/GYN Medical Oncology

Jimmie H. Harvey, MD, Medical Oncology

John B. Casterline, MD, Thoracic Surgeon

Miki Golden, RN, Pain Management

Mary L. Guerry-Force, MD, Chief Pathologist

William A. Thompson, MD, General Surgeon

Samuel Bowen, MD, Neurosurgeon

Sharon D. Gray, MD, Family Practice

Wes Rothrock, MD, Pathology Resident

Lorien Forrest, MD, Pathology Resident

Darryl Hinson, Radiation, Oncology

Gidgett Overton, American Cancer Society

Brandon Haushalter, Assistant Administrator

Gloria Allen, Director of HIM

Bess Searles, Director of Medical Staff Manager

David Tate, Director of Pharmacy

Josh Ivker, MD, Radiology Resident

Joanne Quilon, Resident

Debbie Cox, RN, New Beacon Hospice

James Kamplain, MD, Radiation Oncologist

Arthur A. Jones, MD, Radiologist

Russell G. Beaty, MD, Pulmonologist

Mark S. DeGuenther, MD, Urologist

Brian Larson, MD, Radiation Oncologist

Steven Scarcliff, MD, Surgery Resident

Sandy Barefield, RN, Radiation Oncology


Marie Campbell, RN, PI Coordinator

Yameeka Jones, Assistant Administrator

Debbie Huggart, RN, Women's Boutique

Rick Kolaczek, Director of Radiology

Vanessa McNeil, RN, Oncology Unit Manager





2006 CANCER DATA MANAGEMENT ACTIVITIES

Total number of cancer cases accessioned	774
Total number under active follow-up	5,409
Total number in database	19,730
Follow-up rate	90%


2006 TUMOR BOARD

Meetings	40
Case Presentations	109
Attendance	1660
Trinity Reference Date	1984
Program Approval Period	Through 2009
Requests for Cancer Data	18

The Cancer Data Registry monitors all types of cancer diagnosed and/or treated at Trinity Medical Center and it is a critical element in the evaluation of cancer care. The registry collects demographics, cancer identification, treatment and follow-up data on each eligible cancer patient. These data contribute to the treatment planning, staging and continuity of care for patients.

During 2006, the Cancer Data Registry accessioned 774 cases (672 were new cases diagnosed and treated at Trinity). The other cases had a history of cancer, which had been diagnosed previously and/or diagnosed elsewhere and received part of their treatment at Trinity. The new cases brought the total number in our database to (since the reference date of 1984) 19,730. The total number of living patients actively followed is 5,409 with the follow-up rate of 90%. There were 18 requests for statistical information from the medical staff, residents and students, administration, National Cancer Data Base, state registry, and other healthcare professionals.

Patient data from 2006 was submitted to the National Cancer Data Base with all cases meeting their quality of acceptance criteria. For more information regarding Cancer Registry activities you can reach Connie Jensen at (205) 599-4703 or Annette Entekin at (205) 592-1364. The Cancer Registry is located on the first floor of the hospital just off the main lobby.






CANCER REGISTRY

The Cancer Registry has been a vital component of the cancer program at Trinity Medical Center since 1984. Under the supervision of the Comprehensive Cancer Committee, the Cancer Registry has the responsibility to accurately collect, store, and analyze data on persons diagnosed and/or treated with cancer. All information collected is treated in compliance with the Health Insurance Portability and Accountability ACT (HIPPA) confidentiality requirements. The Cancer Registry is an invaluable tool for the American College of Surgeons Commission on Cancer, and the Joint Commission on Accreditation of Healthcare Organizations approval.

Abstracts for each patient diagnosed and/or treated at Trinity Medical Center are compiled within the database of the Registry. The data abstracted includes patient demographics, medical history, occupational exposures, diagnostic findings, diagnosis, cancer treatment, disease staging and lifetime follow-up. Data accuracy is monitored by the Medical Staff. The reference date of the Cancer Registry is January 1, 1984.

Annual lifetime follow-up of patients is a very important part of the program. Every patient with a diagnosis of cancer is followed on an annual basis. Trinity Medical Center's follow-up rate of 90% is in compliance with the American College of Surgeons Commission on Cancer Standards.

Trinity Medical Center encourages the use of registry data. During 2006, the Cancer Registry received 18 requests for statistical reports. The data in the registry was utilized by hospital administration to investigate the need to update medical equipment needed to serve our patients with cancer. Physicians also used data to compile articles in medical journals and examine treatment methods and modalities. The Cancer Registry also provides required data to the Alabama Statewide Cancer Registry, National Cancer Data Base and American College of Surgeons Commission on Cancer.



CANCER CONFERENCE - 2006

Multidisciplinary Cancer Conferences consist of weekly tumor boards meetings. These conferences serve as a forum to ensure our patients receive the benefits of complete investigational techniques and treatment management. They also serve as an important source of continuing education for our faculty and house staff, providing the most current oncological and surgical information.

For the 2006 year, there were 109 cases presented with 92 being prospective, 17 retrospective, and 14% of our total analytic cases were presented at the tumor board meetings.

Tumor Board (Sites)	Case Presentations
Digestive System	23
Respiratory System	24
Lymphatic System	7
Breast	9
Male Genital	6
Blood/Bone Marrow	6
Urinary System	8
Brain/CNS	2
Endocrine System	10
Female Genital	1
Skin/Melanoma/Soft Tissue	4
Head/Neck	7
Unknown	2

TOTAL CASES: 109

2006 SITE TABULATION

SITE NAME	NUMBER OF CASES		MALE		FEMALE	
LIP	2	0.26	1	50	1	50
BASE OF TONGUE	2	0.26	1	50	1	50
OTHER PARTS OF TONGUE	1	0.13	1	100	0	0
FLOOR OF MOUTH	1	0.13	1	100	0	0
PAROTID GLAND	1	0.13	1	100	0	0
TONSIL	3	0.39	2	66.67	1	33.33
NASOPHARYNX	3	0.39	1	33.33	2	66.67
HYPOPHARYNX	1	0.13	1	100	0	0
OTHER ORAL CAVITY	1	0.13	1	100	0	0
ESOPHAGUS	12	1.55	11	91.67	1	8.33
STOMACH	10	1.29	6	60	4	40
SMALL INTESTINE	5	0.65	3	60	2	40
COLON	63	8.14	35	55.56	28	44.44
RECTOSIGMOID JUNCTION	6	0.78	3	50	3	50
RECTUM	23	2.97	18	78.26	5	21.74
ANUS & ANAL CANAL	4	0.52	2	50	2	50
LIVER & BILE DUCTS	5	0.65	3	60	2	40
OTHER BILIARY TRACT	15	1.94	9	60	6	40
PANCREAS	31	4.01	17	54.84	14	45.16
OTHER DIGESTIVE ORGANS	1	0.13	0	0	1	100
NASAL CAVITY & MIDDLE EAR	1	0.13	1	100	0	0
LARYNX	7	0.9	4	57.14	3	42.86
BRONCHUS & LUNG	125	16.15	79	63.2	46	36.8
HEART MEDIASTINUM PLEURA	6	0.78	6	100	0	0
BLOOD & BONE MARROW	30	3.88	17	56.67	13	43.33
SKIN	23	2.97	10	43.48	13	56.52
RETROPERITONEUM & PERITONEUM	4	0.52	2	50	2	50
CONNECTIVE SUBCUTANEOUS/ SOFT TISSUE	4	0.52	3	75	1	25
BREAST	94	12.14	1	1.06	93	98.94
CORPUS UTERI	5	0.65	0	0	5	100
OVARY	6	0.78	0	0	6	100
PENIS	1	0.13	1	100	0	0
PROSTATE GLAND	124	16.02	124	100	0	0
TESTIS	2	0.26	2	100	0	0
KIDNEY	22	2.84	20	90.91	2	9.09
KIDNEY, RENAL PELVIS	6	0.78	4	66.67	2	33.33
URINARY BLADDER	19	2.45	16	84.21	2	10.53
ORBIT, NOS and OVERLAPPING LESION	1	0.13	1	100	0	0
MENINGES	7	0.9	3	42.86	4	57.14
BRAIN	23	2.97	7	30.43	15	65.22
OTHER NERVOUS SYSTEM	2	0.26	1	50	1	50
THYROID GLAND	19	2.45	6	31.58	13	68.42
OTHER ENDOCRINE GLANDS	8	1.03	3	37.5	5	62.5
OTHER ILL DEFINED SITES	1	0.13	1	100	0	0
LYMPH NODES	31	4.01	20	64.52	10	32.26
UNK PRIMARY	13	1.68	6	46.15	7	53.85
TOTAL CASES	774	100	455	58.79	316	40.83

2006 PRIMARY SITE TABULATION

PRIMARY SITE	TOTAL	CLASS		SEX		STAGE						N/A
		ANALYTIC	NONANALYTIC	M	F	0	I	II	III	IV	UNK	
ALL SITES	771	669	102	455	316	18	86	123	69	62	324	89
ORAL CAVITY	15	13	2	10	5	0	1	1	2	2	9	0
LIP	2	1	1	1	1	0	0	0	0	0	2	0
TONGUE	3	2	1	2	1	0	0	0	0	1	2	0
OROPHARYNX	0	0	0	0	0	0	0	0	0	0	0	0
HYPOPHARYNX	1	1	0	1	0	0	0	0	0	0	1	0
OTHER	9	9	0	6	3	0	1	1	2	1	4	0
DIGESTIVE SYSTEM	175	155	20	107	68	4	21	23	27	27	72	1
ESOPHAGUS	12	10	2	11	1	0	1	0	2	4	5	0
STOMACH	10	9	1	6	4	0	0	0	3	3	4	0
COLON	62	55	7	34	28	1	8	13	14	7	19	0
RECTUM	29	23	6	21	8	2	7	5	2	3	10	0
ANUS/ANAL CANAL	4	1	3	2	2	0	0	0	0	0	4	0
LIVER	5	5	0	3	2	0	0	1	1	1	2	0
PANCREAS	31	30	1	17	14	0	2	1	2	8	18	0
OTHER	22	22	0	13	9	1	3	3	3	1	10	1
RESPIRATORY SYSTEM	139	132	7	90	49	1	25	12	17	18	65	1
NASAL/SINUS	1	1	0	1	0	0	0	1	0	0	0	0
LARYNX	7	7	0	4	3	1	2	1	1	1	1	0
LUNG/BRONCHUS	125	118	7	79	46	0	22	10	14	17	62	0
OTHER	6	6	0	6	0	0	1	0	2	0	2	1
BLOOD & BONE MARROW	31	21	10	18	13	0	0	0	0	0	0	31
LEUKEMIA	17	12	5	10	7	0	0	0	0	0	0	17
MULTIPLE MYELOMA	9	6	3	5	4	0	0	0	0	0	0	9
OTHER	5	3	2	3	2	0	0	0	0	0	0	5
BONE	0	0	0	0	0	0	0	0	0	0	0	0
CONNECT/SOFT TISSUE	4	2	2	3	1	0	1	0	0	0	2	1
SKIN	23	18	5	10	13	0	3	2	3	2	12	1
MELANOMA	19	15	4	9	10	0	3	2	2	2	9	1
OTHER	4	3	1	1	3	0	0	0	1	0	3	0
BREAST	94	83	11	1	93	10	15	17	6	3	42	1
FEMALE GENITAL	11	9	2	0	11	0	3	0	0	2	6	0
CERVIX UTERI	0	0	0	0	0	0	0	0	0	0	0	0
CORPUS UTERI	5	4	1	0	5	0	3	0	0	0	2	0
OVARY	6	5	1	0	6	0	0	0	0	2	4	0
VULVA	0	0	0	0	0	0	0	0	0	0	0	0
OTHER	0	0	0	0	0	0	0	0	0	0	0	0
MALE GENITAL	127	104	23	127	0	0	3	61	8	2	53	0
PROSTATE	124	102	22	124	0	0	2	61	8	2	51	0
TESTIS	2	1	1	2	0	0	1	0	0	0	1	0
OTHER	1	1	0	1	0	0	0	0	0	0	1	0
URINARY SYSTEM	46	39	7	40	6	3	7	5	5	5	21	0
BLADDER	18	15	3	16	2	3	0	2	2	2	9	0
KIDNEY/RENAL	28	24	4	24	4	0	7	3	3	3	12	0
OTHER	0	0	0	0	0	0	0	0	0	0	0	0
BRAIN & CNS	30	25	5	10	20	0	0	0	0	0	0	30
BRAIN (BENIGN)	13	12	1	3	10	0	0	0	0	0	0	13
BRAIN (MALIGNANT)	8	7	1	3	5	0	0	0	0	0	0	8
OTHER	9	6	3	4	5	0	0	0	0	0	0	9
ENDOCRINE	27	24	3	9	18	0	4	0	0	1	14	8
THYROID	19	17	2	6	13	0	4	0	0	1	14	0
OTHER	8	7	1	3	5	0	0	0	0	0	0	8
LYMPHATIC SYSTEM	31	27	4	21	10	0	2	2	1	0	25	1
HODGKIN'S DISEASE	5	4	1	1	4	0	0	1	1	0	3	0
NON-HODGKIN'S	26	23	3	20	6	0	2	1	0	0	22	1
UNKNOWN PRIMARY	13	13	0	6	7	0	0	0	0	0	0	13
OTHER/ILL-DEFINED	5	4	1	3	2	0	1	0	0	0	3	1

Number of cases excluded: 3

This report INCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial neoplasia cases

2006 SITE BY AJCC STAGE TABULATION

SITE NAME	NUMBER CASES	STG 0 (%)		STG I (%)		STG II (%)		STG III (%)		STG IV (%)		STG UNK (%)		N/A (%)		
		0	(%)	I	(%)	II	(%)	III	(%)	IV	(%)	UNK	(%)			
LIP	2	0	0	0	0	0	0	0	0	0	0	2	100	0	0	
BASE OF TONGUE	2	0	0	0	0	0	0	0	0	1	50	1	50	0	0	
OTHER PARTS OF TONGUE	1	0	0	0	0	0	0	0	0	0	0	1	100	0	0	
FLOOR OF MOUTH	1	0	0	0	1	100	0	0	0	0	0	0	0	0	0	
PAROTID GLAND	1	0	0	0	0	0	0	0	0	0	0	1	100	0	0	
TONSIL	3	0	0	0	0	0	0	1	33	1	33	1	33	0	0	
NASOPHARYNX	3	0	0	0	0	1	33	1	33	0	0	1	33	0	0	
HYPOPHARYNX	1	0	0	0	0	0	0	0	0	0	0	1	100	0	0	
OTHER ORAL CAVITY	1	0	0	0	0	0	0	0	0	0	0	1	100	0	0	
ESOPHAGUS	12	2	0	0	1	8	0	0	2	17	4	33	5	42	0	0
STOMACH	10	1	0	0	0	0	0	3	30	3	30	4	40	0	0	
SMALL INTESTINE	5	1	0	0	0	0	1	20	1	20	1	20	2	40	0	0
COLON	63	8	1	2	8	13	13	21	15	24	7	11	19	30	0	0
RECTOSIGMOID JUNCTION	6	1	1	17	1	17	0	0	0	0	1	17	3	50	0	0
RECTUM	23	3	1	4	6	26	5	22	2	9	2	9	7	30	0	0
ANUS & ANAL CANAL	4	1	0	0	0	0	0	0	0	0	0	4	100	0	0	
LIVER & BILE DUCTS	5	1	0	0	0	0	1	20	1	20	1	20	2	40	0	0
OTHER BILIARY TRACT	15	2	1	7	3	20	2	13	1	7	0	0	8	53	0	0
PANCREAS	31	4	0	0	2	6	1	3	2	6	8	26	18	58	0	0
OTHER DIGESTIVE ORGANS	1	0	0	0	0	0	0	0	0	0	0	0	0	1	100	0
NASAL CAVITY & MIDDLE EAR	1	0	0	0	0	0	1	100	0	0	0	0	0	0	0	0
LARYNX	7	1	1	14	2	29	1	14	1	14	1	14	1	14	0	0
BRONCHUS & LUNG	125	16	0	0	22	18	10	8	14	11	17	14	62	50	0	0
HEART MEDIASTINUM PLEURA	6	1	0	0	1	17	0	0	2	33	0	0	2	33	1	17
BLOOD & BONE MARROW	30	4	0	0	0	0	0	0	0	0	0	0	0	30	100	0
SKIN	23	3	0	0	3	13	2	9	3	13	2	9	13	57	0	0
RETROPERITONEUM & PERITONEUM	4	1	0	0	1	25	0	0	0	0	0	0	3	75	0	0
CONNECTIVE SUBCUTANEOUS/ SOFT TISSUE	4	1	0	0	1	25	0	0	0	0	0	0	2	50	1	25
BREAST	94	12	10	11	15	16	17	18	6	6	3	3	42	45	1	1
CORPUS UTERI	5	1	0	0	3	60	0	0	0	0	0	0	2	40	0	0
OVARY	6	1	0	0	0	0	0	0	0	2	33	4	67	0	0	
PENIS	1	0	0	0	0	0	0	0	0	0	0	1	100	0	0	
PROSTATE GLAND	124	16	0	0	2	2	61	49	8	6	2	2	51	41	0	0
TESTIS	2	0	0	0	1	50	0	0	0	0	0	0	1	50	0	0
KIDNEY	22	3	0	0	5	23	3	14	3	14	2	9	9	41	0	0
KIDNEY, RENAL PELVIS	6	1	0	0	2	33	0	0	0	1	17	3	50	0	0	
URINARY BLADDER	19	2	4	21	0	0	2	11	2	11	2	11	9	47	0	0
ORBIT, NOS and OVERLAPPING LESION	1	0	0	0	0	0	0	0	0	0	0	0	0	1	100	0
MENINGES	7	1	0	0	0	0	0	0	0	0	0	0	0	7	100	0
BRAIN	23	3	0	0	0	0	0	0	0	0	0	0	1	4	22	96
OTHER NERVOUS SYSTEM	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	100
THYROID GLAND	19	2	0	0	4	21	0	0	0	1	5	14	74	0	0	
OTHER ENDOCRINE GLANDS	8	1	0	0	0	0	0	0	0	0	0	0	0	8	100	0
OTHER ILL DEFINED SITES	1	0	0	0	0	0	0	0	0	0	0	0	0	1	100	0
LYMPH NODES	31	4	0	0	3	10	2	6	1	3	0	0	24	77	1	3
UNK PRIMARY	13	2	0	0	0	0	0	0	0	0	0	0	0	13	100	0
OVERALL TOTALS	774	100	19	2	87	11	123	16	69	9	62	8	325	42	89	11

Number of cases excluded: 0

This report INCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial neoplasia cases

2006 SITE BY TREATMENT TABULATION

SITE NAME	NUMBER												ALL	
	CASES	(%)	S#	(%)	N#	(%)	R#	(%)	C#	(%)	SR#	(%)	OTHER #s	(%)
LIP	2	0.3	2	100	0	0	0	0	0	0	0	0	0	0
BASE OF TONGUE	2	0.3	0	0	0	0	0	0	1	50	1	50	0	0
OTHER PARTS OF TONGUE	1	0.1	0	0	1	100	0	0	0	0	0	0	0	0
FLOOR OF MOUTH	1	0.1	1	100	0	0	0	0	0	0	0	0	0	0
PAROTID GLAND	1	0.1	1	100	0	0	0	0	0	0	0	0	0	0
TONSIL	3	0.4	0	0	0	0	0	0	1	33	1	33	1	33
NASOPHARYNX	3	0.4	0	0	0	0	0	0	0	0	0	0	3	100
HYPOPHARYNX	1	0.1	0	0	0	0	0	0	0	0	0	0	1	100
OTHER ORAL CAVITY	1	0.1	0	0	1	100	0	0	0	0	0	0	0	0
ESOPHAGUS	12	1.6	3	25	4	33	1	8	0	0	1	8	3	25
STOMACH	10	1.3	5	50	2	20	0	0	0	0	0	0	3	30
SMALL INTESTINE	5	0.6	3	60	0	0	0	0	0	0	0	0	2	40
COLON	63	8.1	42	67	4	6	0	0	1	2	0	0	16	25
RECTOSIGMOID JUNCTION	6	0.8	4	67	0	0	0	0	0	0	0	0	2	33
RECTUM	23	3	13	57	1	4	0	0	0	0	0	0	9	39
ANUS & ANAL CANAL	4	0.5	0	0	1	25	0	0	1	25	0	0	2	50
LIVER & BILE DUCTS	5	0.6	2	40	3	60	0	0	0	0	0	0	0	0
OTHER BILIARY TRACT	15	1.9	7	47	6	40	0	0	0	0	0	0	2	13
PANCREAS	31	4	3	10	18	58	1	3	2	6	0	0	7	23
OTHER DIGESTIVE ORGANS	1	0.1	1	100	0	0	0	0	0	0	0	0	0	0
NASAL CAVITY & MIDDLE EAR	1	0.1	1	100	0	0	0	0	0	0	0	0	0	0
LARYNX	7	0.9	1	14	2	29	1	14	0	0	0	0	3	43
BRONCHUS & LUNG	125	16.1	32	26	36	29	13	10	12	10	7	6	25	20
HEART MEDIASTINUM PLEURA	6	0.8	1	17	2	33	1	17	0	0	1	17	1	17
BLOOD & BONE MARROW	30	3.9	0	0	16	53	2	7	8	27	0	0	4	13
SKIN	23	3	18	78	2	9	2	9	0	0	1	4	0	0
RETROPERITONEUM & PERITONEUM	4	0.5	2	50	1	25	0	0	1	25	0	0	0	0
CONNECTIVE SUBCUTANEOUS/ SOFT TISSUE	4	0.5	1	25	3	75	0	0	0	0	0	0	0	0
BREAST	94	12.1	40	43	17	18	1	1	2	2	15	16	19	20
CORPUS UTERI	5	0.6	4	80	0	0	0	0	0	0	1	20	0	0
OVARY	6	0.8	1	17	3	50	0	0	0	0	0	0	2	33
PENIS	1	0.1	1	100	0	0	0	0	0	0	0	0	0	0
PROSTATE GLAND	124	16	46	37	13	10	37	30	0	0	2	2	26	21
TESTIS	2	0.3	2	100	0	0	0	0	0	0	0	0	0	0
KIDNEY	22	2.8	18	82	4	18	0	0	0	0	0	0	0	0
KIDNEY, RENAL PELVIS	6	0.8	3	50	1	17	1	17	1	17	0	0	0	0
URINARY BLADDER	19	2.5	13	68	3	16	0	0	0	0	1	5	2	11
ORBIT, NOS and OVERLAPPING LESION	1	0.1	0	0	1	100	0	0	0	0	0	0	0	0
MENINGES	7	0.9	0	0	7	100	0	0	0	0	0	0	0	0
BRAIN	23	3	9	39	9	39	1	4	0	0	0	0	4	17
OTHER NERVOUS SYSTEM	2	0.3	1	50	1	50	0	0	0	0	0	0	0	0
THYROID GLAND	19	2.5	8	42	2	11	0	0	0	0	8	42	1	5
OTHER ENDOCRINE GLANDS	8	1	1	13	7	88	0	0	0	0	0	0	0	0
OTHER ILL DEFINED SITES	1	0.1	0	0	0	0	0	0	0	0	0	0	1	100
LYMPH NODES	31	4	3	10	12	39	1	3	11	35	0	0	4	13
UNK PRIMARY	13	1.7	0	0	12	92	0	0	1	8	0	0	0	0
OVERALL TOTALS	774	100	293	38	195	25	62	8	42	5	39	5	143	18

S = SURGERY
N = NONE
R = RADIATION
C = CHEMOTHERAPY
SR = SURGERY/RADIATION

This report was run with the following criteria:


Include CA in-situ cervix cases, squamous & basal cell skin cases, and intraepithelial neoplasia cases

Include only the first course of treatments

Include all treatment hospitals

2006 TREATMENT COMBINATION GRAPH

TREATMENT TYPE	NUMBER OF CASES	PERCENT
SURGERY	293	40.36%
NONE	195	26.86%
RADIATION	62	8.54%
CHEMOTHRAPY	42	5.79%
SURG/RAD	39	5.37%
SURG/CHEM	30	4.13%
SURG/CHEM/RAD	25	0.03443526
CHEM/RAD	25	3.44%
RAD/HORMONES	15	2.07%
TOTAL CASES	726	100.00%




2006 SITE BY RACE TABULATION

SITE NAME	NUMBER		WHITE		BLACK		ASIAN		OTHER	
	CASES	(%)	NUMBER	(%)	NUMBER	(%)	NBR	(%)	NBR	(%)
LIP	2	0	2	100	0	0	0	0	0	0
BASE OF TONGUE	2	0	2	100	0	0	0	0	0	0
OTHER PARTS OF TONGUE	1	0	0	0	1	100	0	0	0	0
FLOOR OF MOUTH	1	0	1	100	0	0	0	0	0	0
PAROTID GLAND	1	0	1	100	0	0	0	0	0	0
TONSIL	3	0	3	100	0	0	0	0	0	0
NASOPHARYNX	3	0	1	33	2	67	0	0	0	0
HYPOPHARYNX	1	0	1	100	0	0	0	0	0	0
OTHER ORAL CAVITY	1	0	1	100	0	0	0	0	0	0
ESOPHAGUS	12	2	10	83	2	17	0	0	0	0
STOMACH	10	1	10	100	0	0	0	0	0	0
SMALL INTESTINE	5	1	3	60	2	40	0	0	0	0
COLON	63	8	55	87	8	13	0	0	0	0
RECTOSIGMOID JUNCTION	6	1	4	67	2	33	0	0	0	0
RECTUM	23	3	21	91	2	9	0	0	0	0
ANUS & ANAL CANAL	4	1	4	100	0	0	0	0	0	0
LIVER & BILE DUCTS	5	1	3	60	2	40	0	0	0	0
OTHER BILIARY TRACT	15	2	15	100	0	0	0	0	0	0
PANCREAS	31	4	24	77	7	23	0	0	0	0
OTHER DIGESTIVE ORGANS	1	0	1	100	0	0	0	0	0	0
NASAL CAVITY & MIDDLE EAR	1	0	1	100	0	0	0	0	0	0
LARYNX	7	1	4	57	3	43	0	0	0	0
BRONCHUS & LUNG	125	16	107	86	17	14	1	1	0	0
HEART MEDIASTINUM PLEURA	6	1	6	100	0	0	0	0	0	0
BLOOD & BONE MARROW	30	4	24	80	6	20	0	0	0	0
SKIN	23	3	23	100	0	0	0	0	0	0
RETROPERITONEUM & PERITONEUM	4	1	1	25	3	75	0	0	0	0
CONNECTIVE SUBCUTANEOUS/ SOFT TISSUE	4	1	3	75	1	25	0	0	0	0
BREAST	94	12	84	89	10	11	0	0	0	0
CORPUS UTERI	5	1	4	80	0	0	0	0	1	20
OVARY	6	1	5	83	1	17	0	0	0	0
PENIS	1	0	1	100	0	0	0	0	0	0
PROSTATE GLAND	124	16	78	63	42	34	0	0	4	3
TESTIS	2	0	2	100	0	0	0	0	0	0
KIDNEY	22	3	19	86	3	14	0	0	0	0
KIDNEY, RENAL PELVIS	6	1	5	83	0	0	1	17	0	0
URINARY BLADDER	19	2	17	89	1	5	0	0	1	5
ORBIT, NOS and OVERLAPPING LESION	1	0	1	100	0	0	0	0	0	0
MENINGES	7	1	6	86	1	14	0	0	0	0
BRAIN	23	3	18	78	4	17	0	0	1	4
OTHER NERVOUS SYSTEM	2	0	2	100	0	0	0	0	0	0
THYROID GLAND	19	2	18	95	1	5	0	0	0	0
OTHER ENDOCRINE GLANDS	8	1	8	100	0	0	0	0	0	0
OTHER ILL DEFINED SITES	1	0	1	100	0	0	0	0	0	0
LYMPH NODES	31	4	29	94	0	0	0	0	2	6
UNK PRIMARY	13	2	11	85	2	15	0	0	0	0
OVERALL TOTALS	774	100	640	83	123	16	2	0	9	1

NOTE: ASIAN INCLUDES- ASIAN INDIAN, PAKISTANI, AND OTHER ASIAN
 OTHER INCLUDES- ALL RACES NOT LISTED ABOVE AND/OR UNKNOWN


2006 Age By Sex Graph

Age Range	Male	Female
20 - 29	3	12
30 - 39	15	21
40 - 49	34	27
50 - 59	93	59
60 - 69	131	76
70 - 79	125	59
80 - 89	42	56
90 - 99	4	5
TOTALS	447	315




2006 Stage By Sex Graph

Stage	Male	Female
0	5	13
I	45	41
II	91	32
III	43	26
IV	35	27
UNKNOWN	196	128
N/A	40	49
TOTALS	455	316



2006 TNM STAGE GROUP

TNM STAGE GROUP	NUMBER CASES	PERCENT
0	19	2.45%
I	87	11.24%
II	123	15.89%
III	69	8.91%
IV	62	8.01%
UNKNOWN	325	41.99%
N/A	89	11%
TOTAL CASES	774	100.00%





LYMPHOMA

Lymphomas are cancers that begin with the malignant transformation of a lymphocyte. The lymphomas are divided in two major categories. Hodgkin lymphoma and all other lymphomas, called Non-Hodgkin lymphoma.

Lymphomas result from an injury to the DNA of a lymphocyte. Scientists know that the damage to the DNA is acquired (it occurs after birth) rather than inherited.


Lymphomas generally start either in lymph nodes or in lymphatic tissue found in organs such as the stomach or intestines. In many cases the lymphomas involve the bone marrow and can infiltrate organs such as the liver and spleen.

Signs and symptoms of lymphoma include painless swelling of lymph nodes in the neck, armpit, groin and abdomen. There is also recurrent high fever, night sweats, excessive fatigue, indigestion, abdominal pain, weight loss, troublesome itching, appetite loss and bone pain.

Most cases of Hodgkin lymphoma occur in people who do not have identifiable risk factors. Hodgkin lymphoma has characteristics that distinguish it from all other cancers of the lymphatic system, including the presence of an abnormal cell called the Reed-Sternberg cell. Hodgkin lymphoma has a higher incidence rate in adolescents and young adults. The cure rate for Hodgkin lymphoma has more than doubled from 1960 to 2001. It is now considered one of the most curable forms of cancer.

Non-Hodgkin lymphoma represents a diverse group of cancers with the distinctions between types based on the characteristics of the cancerous cells. The groups are often classified as indolent, aggressive or low, intermediate and high grade. Each histological grouping is diagnosed and treated differently, and each has prognostic factors that categorize it as more or less favorable. Early stage localized Non-Hodgkin lymphoma is sometimes treated with radiation alone depending on the tumor size, cell type and location of the lymphoma. Widespread disease requires chemotherapy or chemotherapy and/or monoclonal antibody therapy with radiation. Non-Hodgkin lymphoma is the eighth most common cause of cancer deaths in males and seventh most common cause of death in females. The five-year relative survival rate has risen from 47.3 percent in 1974 to 60.2 percent in 2001.

The annual incidence of Non-Hodgkin lymphoma has nearly doubled over the last fifty years. The likely causes for increasing incidence includes the use of herbicides and pesticides in farming, as well as the spread of HIV within the population and immunosuppression after transplantation. Certain






LYMPHOMA - continued

chemotherapeutic agents are also associated with later onset of lymphomas.

“Staging” is the term used for determining the extent of disease. Staging provides important information to the physician planning treatment. In most cases, procedures such as bone marrow examination, CT scans, and most recently, PET scans allow for very accurate determination of the organs involved. Treatment recommendations are based on the results of staging. Early stage lymphomas involving only one lymph node region are often treated with radiation therapy alone. More extensive disease involving multiple lymph node regions or other organs requires systemic chemotherapy usually with a combination of three to four drugs. The newer monoclonal antibodies have added an additional weapon against Non-Hodgkin lymphoma. These are “targeted therapies” which bind to specific proteins on the surface of lymphocytes, allowing tumor cells to be killed by the body’s immune system. Newer approaches to monoclonal antibody treatment allow even better remission rates and hopefully, long term care. The intense focus of research has translated into more effective therapy and ultimately, into improvement in survival.

Here at Trinity Medical Center, the results of the Non-Hodgkin lymphoma are as follows.



NON-HODGKIN LYMPHOMA STUDY FROM 2006 CASES

Case #	Dx	M/ F	Age	R*	A/E/ Survival**	Cell Type	Site	Co-Morbidities	Types of Treatment
794701	11/13/06	F	71		Alive	B-cell	Inguinal Nodes Groin	401.9,427.31 714.0, 278.0	Exploratory procedure and biopsy of lymph nodes
620732	6/15/93	M	40	R	Alive	Unk	Scalp	None	Pt dx and tx at UAB in 1993 with 2000 cGy in 10 fractions to rt scalp. Now with recurrence.
287142	10/13/06	F	66		Alive	B-cell	Nodes from both sides of diaphragm	491.2, 401.9, 285.9	CHOP, Rituxan
596759	11/11/02	M	43	R	Alive	Unk	Intra- abdominal	288.0, 463, 475	Per Dr Harvey, tx with Rituxan, Cytoxin, Fludara. Now awaiting bone marrow transplant at UAB
328761	1/27/06	F	43		Expired 8 mos	B-Cell	Abdomen	070.54,571.5, 789.5, 416.8 401.9,714.0	Liver bx with splenectomy and incidental finding of Non-Hodgkin Lymphoma. Tx w/ Adriamycin, Oncovin, Cytoxin, Rituxan
579675	2/28/06	M	49		Alive	B-cell	Intrathoracic	590.8,263.9 486, 112.0, 518.81, 786.3 787.91, 414.8, 458.9, 530.81	Two rounds of CHOP; Other cancer directed therapy. Dx at Kirkland Clinic...came here for 2 nd opinion.
796380	11/28/06	F	39		Alive	B-cell	Lt axillary nodes	493.9	CHOP plus Rituxan


* Recurrent ** Alive/Expired/Survival

Codes:

070.54 - Chronic Hepatitis 112.0 - Candidiasis of Mouth 263.9 – Protein-Calorie Malnutrition 278.0 – Obesity 285.9 - Anemia 288.0 - Agranulocytosis 401.9 – Hypertension 414.8 - Chronic Ischemic Heart Disease	416.8 – Chronic Pulmonary Heart Disease 427.31 - Atrial Fibrillation 458.9 – Hypotension 463 - Acute Tonsillitis Abscess 475 – Peritonsillar Abscess 486 – Pneumonia 491.21 – Obstructive Chronic Bronchitis 493.9 - Asthma	518.81 – Acute Respiratory Failure 530.81 – Esophageal Reflux 571.5 – Cirrhosis of Liver 590.8 – Pyelonephritis 714.0 – Rheumatoid Arthritis 786.3 – Hemoptysis 787.91 – Diarrhea 789.5 - Ascites
--	--	--

Conclusions: Of the seven cases diagnosed in our database, four were female and three were male. Two of the cases were recurrences. Six of the cases are still alive. The patient who expired had other co-morbidities that would have been life threatening.

GENDER of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005
 Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems
 Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals



Source: NCDB, CoC, ACoS.

Benchmark Reports, v9.0 - January 11, 2008

GENDER of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005

Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems
 Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals


	N (cases)		% (percent)	
	Sum		Sum	
	Reported by		Reported by	
	Other	My Hosp.	Other	My Hosp.
GENDER				
Male	7,204	71	53.22	53.79
Female	6,331	61	46.78	46.21
Total	13,535	132	100.00	100.00

Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0

RACE of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005

Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems

Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals



Source: NCDB, CoC, ACoS.

Benchmark Reports, v9.0 - January 11, 2008

RACE of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005


Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems

Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals

	N (cases)		% (percent)	
	Sum		Sum	
	Reported by		Reported by	
	Other	My Hosp.	Other	My Hosp.
RACE				
White	11,720	115	86.59	87.12
Black	1,544	12	11.41	9.09
Hispanic	90	0	0.66	0.00
Native American	8	0	0.06	0.00
Asian/Pacific Islands	64	0	0.47	0.00
Other/Unknown	109	5	0.81	3.79
Total	13,535	132	100.00	100.00

Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0

RADIATION of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005
 Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems
 Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals



Source: NCDB, CoC, ACoS.

Benchmark Reports, v9.0 - January 11, 2008

RADIATION of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005
 Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems
 Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals


RADIATION	N (cases)		% (percent)	
	Sum		Sum	
	Reported by		Reported by	
	Other	My Hosp.	Other	My Hosp.
No Rad.	11,365	117	83.97	88.64
Beam Rad.	2,136	15	15.78	11.36
BrachyTher.	2	0	0.01	0.00
Radioisotopes	4	0	0.03	0.00
Rad. Ther., NOS	28	0	0.21	0.00
Total	13,535	132	100.00	100.00

Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0

STAGE of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005

Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems

Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals



Source: NCDB, CoC, ACoS.

Benchmark Reports, v9.0 - January 11, 2008

STAGE of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005


Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems

Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals

STAGE	N (cases)		% (percent)	
	Sum		Sum	
	Reported by		Reported by	
	Other	My Hosp.	Other	My Hosp.
I	3,497	23	25.84	17.42
II	1,903	22	14.06	16.67
III	1,870	12	13.82	9.09
IV	3,465	12	25.60	9.09
Unknown	2,800	63	20.69	47.73
Total	13,535	132	100.00	100.00

Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0

SURGERY of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005
 Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems
 Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals



Source: NCDB, CoC, ACoS.


Benchmark Reports, v9.0 - January 11, 2008

SURGERY of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005
 Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems
 Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals

	N (cases)		% (percent)	
	Sum		Sum	
	Reported by		Reported by	
	Other	My Hosp.	Other	My Hosp.
SURGERY				
None; no Surg. of primary site	9,128	102	67.44	77.27
Surg., NOS	4,166	29	30.78	21.97
Unknown if Surg. performed	241	1	1.78	0.76
Total	13,535	132	100.00	100.00

Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0

THERAPY of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005
 Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems
 Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals



Source: NCDB, CoC, ACoS.

Benchmark Reports, v9.0 - January 11, 2008


THERAPY of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005

Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems
 Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals

THERAPY	N (cases)		% (percent)	
	Sum		Sum	
	Reported by		Reported by	
	Other	My Hosp.	Other	My Hosp.
No Systemic Ther.	5,202	61	38.43	46.21
Chem. Alone	5,483	66	40.51	50.00
Horm. Ther. Alone	64	1	0.47	0.76
Immuno. Alone	209	0	1.54	0.00
Chem. and Horm. Ther.	1,305	3	9.64	2.27
Chem. and Immuno.	521	1	3.85	0.76
Horm. Ther. and Immuno.	11	0	0.08	0.00
Chem., Horm. Ther. and Immunotherapy	740	0	5.47	0.00
Total	13,535	132	100.00	100.00

Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0

TREATMENT of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005
 Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems
 Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals



Source: NCDB, CoC, ACoS.

Benchmark Reports, v9.0 - January 11, 2008

TREATMENT of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005


Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems
 Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals

TREATMENT	N (cases)		% (percent)	
	Sum		Sum	
	Reported by		Reported by	
	Other	My Hosp.	Other	My Hosp.
Surg. Only	1,583	13	11.70	9.85
Rad. Only	529	5	3.91	3.79
Surg. & Chem.	1,151	14	8.50	10.61
Rad. & Chem.	630	6	4.65	4.55
Chem. Only.	3,435	44	25.38	33.33
Chem. & Horm. Ther.	721	2	5.33	1.52
Chem., Horm. Ther. & BRM	403	0	2.98	0.00
Other Specified Ther.	2,367	6	17.49	4.55
No 1st Course Rx	2,716	42	20.07	31.82
Total	13,535	132	100.00	100.00

Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0

YEAR of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005

Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems
 Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals



Source: NCDB, CoC, ACoS.

Benchmark Reports, v9.0 - January 11, 2008

YEAR of Non-Hodgkins Lymphoma Cancer Diagnosed 2000 to 2005

Cases Dx and All/Part First Course Rx at Reporting Facility - HOSP. TYPE: All Types/Systems
 Trinity Medical Center, Birmingham, AL vs Hospitals in ACS Division: Mid-South - Data From 124 Hospitals

YEAR	N (cases)		% (percent)	
	Sum		Sum	
	Reported by		Reported by	
	Other	My Hosp.	Other	My Hosp.
2000	2,432	19	17.97	14.39
2001	2,128	24	15.72	18.18
2002	2,227	18	16.45	13.64
2003	2,205	24	16.29	18.18
2004	2,282	22	16.86	16.67
2005	2,261	25	16.70	18.94
Total	13,535	132	100.00	100.00

Source: NCDB, Commission on Cancer, ACoS. Benchmark Reports, v9.0



COMMUNITY OUTREACH

During the 2006 calendar year, there were a total of 6 Health Fairs that offered skin cancer screenings. These events were held at the following locations:

- Alabama Power
- Avondale Elementary
- BE & K
- Hoover Recreation Center
- Southern Nuclear

A total of **444** individuals took advantage of being screened at these events.

A total of **6** cancer-related health seminars were also held during 2006. A listing of those events and cancer sites screened are as follows:

- Alabama Power – Skin Cancer
- Birmingham Water Works Board – Cervical/Ovarian
- Birmingham Water Works Board – Colon Cancer
- Birmingham Water Works Board - Prostate Cancer
- Daniel Corporation – Cancer of Female Reproductive System
- Southland Tube – Lung Cancer

A total of **86** employees attended these events.

ACKNOWLEDGEMENTS

The Cancer Center is pleased to present the 2007 Annual Report reflecting 2006 data and activities to the medical staff and community. This report was produced by Connie Jensen, Annette Entrekin, Tricia Chamblee, Corey Anders and Leisha Harris. Special appreciation is extended to Dr. Jimmie Harvey and to the Comprehensive Cancer Committees at Trinity, whose members were responsible for sharing their expertise and critiquing this report. As always, we express our gratitude to the members of Trinity Medical Center Administration.

